Revenue expanding at 45% annually demonstrates genuine early commercial traction, but negative free cash flow at 52% of revenue, a single confirmatory Phase 3 trial as the decisive catalyst, and 25% short interest mark this as a high-asymmetry situation where the upside scenario demands both clinical success and consistent execution.
Thesis pillars
- Concentrated Short Interest Overhang↑Improving
- Confirmatory Trial Single Asset Dependency↑Improving
- Revenue Growth Against Cash Consumption→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.83: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling two products: Amtagvi® (lifileucel), the first approved one-time T cell therapy for a solid tumor cancer (advanced melanoma), and Proleukin® (aldesleukin), an IL-2 used in the Amtagvi regimen. The... Read more
Sell if holding. Engine safety override at $8.83: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 6.0/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news boost analyst 0.40, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 0d<=7d. Suitability: speculative.
About Iovance Biotherapeutics, Inc.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics commercially launched Amtagvi (lifileucel) — the first FDA-approved one-time T cell therapy for a solid tumor cancer — in the U.S. in Q2 2024, and sells Proleukin (aldesleukin) acquired from Clinigen in May 2023. The company reported a net loss of $391.0 million for the year ended December 31, 2025, with an accumulated deficit of $2.8 billion and $303.0 million in cash. Amtagvi is approved in the U.S. and Canada; potential approvals are pending in the UK and Australia in H1 2026 and Switzerland in 2027.
Iovance sells Amtagvi through a growing authorized treatment center (ATC) network, with revenue recognized upon patient infusion; Proleukin is sold to three main U.S. distributors and distributors outside the U.S. across three channels — use in the Amtagvi treatment regimen, use in manufacturing processes for cell therapies, and clinical and research settings. All Amtagvi manufacturing transferred to the Iovance Cell Therapy Center (iCTC) in Philadelphia after the Minaris contract terminated in Q1 2026; the iCTC is the sole FDA-approved facility with a centralized TIL manufacturing process and potential capacity for more than 5,000 patients annually. Proleukin supply comes from Boehringer Ingelheim Biopharmaceuticals GmbH under a supply agreement extended through December 31, 2028 with minimum annual vial commitments. The company pays royalties ranging from less than one to mid-single-digit percent of net sales to the NIH under a patent license agreement extended to August 2029.
Show full overview
The confirmatory Phase 3 trial TILVANCE-301 — randomizing approximately 670 frontline advanced melanoma patients — serves a dual purpose: establishing a registrational path for lifileucel combined with pembrolizumab and generating data to support full U.S. approval for Amtagvi in previously treated patients. The company withdrew an initial EU marketing authorization application in July 2025 and plans to resubmit a centralized MAA to the EMA in 2026; if the resubmission does not receive approval, the addressable patient population outside the U.S. and Canada could be materially constrained.
See also: Healthcare · Biotechnology
From Iovance Biotherapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Iovance Biotherapeutics, Inc.
Latest news
- NEWS UBS Maintains Neutral Rating on Iovance Biotherapeutics and Raises Price Target to $8 — fiscal.ai Nov 3, 2026 positive
- NEWS UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8 — benzinga Nov 3, 2026 positive
- NEWS Crude Oil Moves Lower; Caterpillar Shares Fall Following Q3 Results — benzinga Oct 29, 2026 neutral
- NEWS 12 Health Care Stocks Moving In Thursday's Intraday Session — benzinga Oct 29, 2026 neutral
- NEWS Iovance Biotherapeutics (IOVA) Stock Price Trails Record Revenue And Margin Gains - simplywall.st — simplywall.st Aug 8, 2026 positive
Latest item Nov 3, 2026 · Generated 2026-11-04T11:39:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductAmtagvi® (lifileucel)10-K Item 1: 'Our top priority is to drive commercial success of Amtagvi® for previously treated advanced melanoma'
- HIGHpipelineTILVANCE-301 (Amtagvi confirmatory Phase 3)10-K Item 1: 'TILVANCE-301, is designed to support a registrational path for lifileucel ... to support full U.S. approval for Amtagvi® in post-anti-PD-1 advanced melanoma'
- MEDIUMSupplierBoehringer Ingelheim (Proleukin® manufacturer)10-K Item 1: 'manufacturing and supply agreement with Boehringer Ingelheim Biopharmaceuticals GmbH, to carry out the processing, manufacturing, and supply of Proleukin® in unlabeled vials'
Material Events(8-K, last 90d)
- 2026-03-20Item 5.02LOWBoard director Wendy Yarno gave notice March 17, 2026 she will retire and not stand for re-election at the June 2026 annual meeting. Will serve out current term. No disagreement with company operations, policies, or practices cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.83: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 2.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $8.21. Score 6.0/10, moderate confidence.
Analyst target: $12.44 (+40.9% upside). Prior stop was $8.21. Stop-loss: $8.21.
Concentration risk — Pipeline: TILVANCE-301 (Amtagvi confirmatory Phase 3); Quality below floor (3.1 < 4.0).
Iovance Biotherapeutics, Inc. trades at a P/E of N/A (forward -45.1). TrendMatrix value score: 6.2/10. Verdict: Sell.
16 analysts rate IOVA, with a consensus score of 4.0/5. 10 analysts publish price targets averaging $14.
What does Iovance Biotherapeutics, Inc. do?Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling two products: Amtagvi® (lifileucel),...
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling two products: Amtagvi® (lifileucel), the first approved one-time T cell therapy for a solid tumor cancer (advanced melanoma), and Proleukin® (aldesleukin), an IL-2 used in the Amtagvi regimen. The company reported a net loss of $391.0 million in 2025 with $303.0 million in cash, scaling Amtagvi's authorized treatment center network while pursuing approvals in the UK, Australia, and EU.